Peripheral Nerve Stimulator for pain relief cleared by FDA

3rd August 2017
Posted By : Enaie Azambuja
Peripheral Nerve Stimulator for pain relief cleared by FDA

Xavant Technology has announced that the U.S. FDA cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency (PRF) waveform, this non-invasive neuromodulation device is focused on the symptomatic relief and management of chronic intractable pain, as well as an adjunctive treatment in the management of post-surgical pain, post-traumatic acute pain problems, and an adjunct for pain control due to rehabilitation.

The need for this device is profound. More than 100 million Americans report that they have a problem with pain. Chronic pain is characterised by neuroplastic changes that cause sensitisation of the nervous system.

These changes result in anatomical and physiological changes that affect neurological function, which causes long-term potentiation and gene expression changes that then allow the pain to continue with or without further peripheral input, and a lower pain threshold; this dysfunction then also accounts for the epiphenomena associated with the disease, including emotional, memory, and motor changes, which then becomes the illness of chronic pain.

Treatment of chronic pain in the United States is estimated to cost $600 billion annually. The current standard of care for chronic pain includes drug cocktails such as Corticosteroids, Opiate pain relievers, injections, and beyond combined with treatments like physical therapy and counseling. Treatments can come with various short-term and long-term side effects.

The Stimpod NMS460, however, will greatly impact the industry as a non-invasive, non-drug solution with zero side effects and a fast onset of effect at a fraction of the cost of comparable treatments. The device applies its patented PRF waveform to the affected area transcutaneously.

This waveform creates electromagnetic effects similar to invasive pulsed radio frequency treatments, and several case studies have shown instant and dramatic relief of chronic intractable pain.

The Stimpod NMS460 also incorporates the nerve-locating technology which features a nerve mapping probe that enables practitioners to locate nerves and evaluate the treatment progress of damaged nerves. Bell Medical has been selected as the master distributor for both the U.S. and Canada.

"We are thrilled at the news that our revolutionary device can now be used in the U.S.," said Corlius Birkill, CEO of Xavant Technology (Pty) Ltd. "This groundbreaking technology has the ability to help tens if not hundreds of millions of people just in the U.S. as a valuable treatment asset for neurologists, chiropractors, acupuncturists, physical therapists, physiatrists, and medical pain practitioners."

Downloads


You must be logged in to comment

Write a comment

No comments




More from Xavant Technology

Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

SPE Offshore Europe 2017
5th September 2017
United Kingdom Aberdeen Exhibition & Conference Centre
EPE 2017 ECCE Europe
11th September 2017
Poland Warsaw
ON Semiconductor Power Seminars 2017
11th September 2017
United Kingdom
DSEI 2017
12th September 2017
United Kingdom ExCeL, London
RWM 2017
12th September 2017
United Kingdom NEC, Birmingham